When combined with glycoprotein 130 (gp130, synonyms: IL6ST or CD130) interleukin-6 can regulate disease progression through the Shp2-Ras-ERK, JAK1/2-STAT3, and PI3K-Akt-mTOR pathways, and its higher serum levels were associated with larger tumor size, presence of metastases, and worse overall- and disease-free survival [40,41,45,46]. The gene discussed is MTOR; the disease is neoplasm.